# InStride Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/instride-health

- Industry: Healthcare Specialists
- Headquarters: Wellesley, US
- Website: www.instride.health
- Total disclosed funding: $80M
- Latest round: Series C (Jun 15, 2026)
- Investors on record: 7

## About

InStride Health, Inc. is a US-based firm specializing in outpatient programs for pediatric anxiety and obsessive-compulsive disorder (OCD), delivering evidence-based treatment through virtual platforms to support young individuals and their families.Founded in 2021 by James McElhiney, John Voith, Kathryn Boger, and Mona Potter, InStride Health, Inc. is headquartered in Wellesley, US.  InStride Health provides specialized outpatient treatment programs targeting pediatric anxiety and OCD for children, teenagers, and young adults aged 7 to 24. The programs utilize cognitive behavioral therapy (CBT) and exposure therapy, delivered virtually to ensure real-time support and personalized care plans. The company operates across various US markets, including Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, North Carolina, Texas, Virginia, and Washington, D.C., catering to families seeking effective treatment.InStride Health's revenue model is based on subscription services and direct-to-consumer transactions, primarily from its outpatient programs which are usually covered by major insurance providers. Clients enroll in the treatment program according to their insurance agreements, which may involve co-pays or out-of-pocket expenses. This model is designed to promote long-term engagement with families, providing continuous support and resources throughout the treatment process. In June 2026, InStride Health, Inc. raised USD 30 million in series C funding co-led by Echo Health Ventures and FMZ Venture, with participation from Mass General Brigham Ventures, General Catalyst Partners, .406 Ventures, and Valtruis. The company will use the June 2026 funding to support the further development of its products and expansion plans initiatives.

## Funding rounds

- Series C, Jun 15, 2026, $30M — General Catalyst Partners, .406 Ventures, Mass General Brigham Ventures, Echo Health Ventures, FMZ Ventures, Valtruis
- Series B, Mar 27, 2024, $30M — General Catalyst Partners, .406 Ventures, Mass General Brigham Ventures, Valtruis, Hopelab
- Series A, Oct 3, 2022, $20M — .406 Ventures, Mass General Brigham Ventures, Valtruis

## Investors

- .406 Ventures (https://capitalatlas.ai/funds/406-ventures) — Series A, Series B, Series C
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B, Series C
- Valtruis — Series A, Series B, Series C
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B, Series C
- Hopelab — Series B
- Echo Health Ventures (https://capitalatlas.ai/funds/echo-health-ventures) — Series C
- FMZ Ventures (https://capitalatlas.ai/funds/fmz-ventures) — Series C